Therapies for Prevention and Treatment of Alzheimer's Disease

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Mendiola Precoma, J ^a   Berumen, L C ^a   Padilla, K ^a   Garcia Alcocer, G ^a  

^a UNIVERSIDAD AUTÓNOMA DE QUERÉTARO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ADUCANUMAB; ALKALOID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BAN 2401; BAPINEUZUMAB; CHOLINESTERASE INHIBITOR; CLIOQUINOL; CRENEZUMAB; CYCLIN DEPENDENT KINASE 5; ENCENICLINE; EPIGALLOCATECHIN GALLATE; FLAVONOID; GANTENERUMAB; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUCOMETHYLTHIONINIUM; METHYLENE BLUE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NOOTROPIC AGENT; PROBIOTIC AGENT; PROTEINASE INHIBITOR; RESVERATROL; SCYLLOINOSITOL; SOLANEZUMAB; TERPENOID; TIDEGLUSIB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL FEATURE; DIET THERAPY; DRUG TARGETING; GENETIC SUSCEPTIBILITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INTESTINE FLORA; LATE ONSET DISORDER; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PALLIATIVE THERAPY; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; PATHOPHYSIOLOGY; RISK FACTOR;

ALZHEIMER DISEASE; HUMANS; OBESITY; RISK FACTORS;

EID: 84982106547     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/2589276     Document Type: Review

References (224)

1. C. Van Cauwenberghe, C. Van Broeckhoven, and K. Sleegers, "The genetic landscape of Alzheimer disease: clinical implications and perspectives, " Genetics in Medicine, vol. 18, no. 5, pp. 421-430, 2015.
2. S. Chakrabarti, V. K. Khemka, A. Banerjee, G. Chatterjee, A. Ganguly, and A. Biswas, "Metabolic risk factors of sporadic Alzheimer's disease: implications in the pathology, pathogenesis and treatment, " Aging and Disease, vol. 6, no. 4, pp. 282-299, 2015.
3. T. D. Bird, "Early-onset familial Alzheimer disease, " in GeneReviews, R. Pagon, M. Adam, H. Ardinger et al., Eds., pp. 1-42, University ofWashington, Seattle, Seattle, Wash, USA, 2012.
4. L. W. Chu, "Alzheimer's disease: early diagnosis and treatment, " Hong Kong Medical Journal, vol. 18, no. 3, pp. 228-237, 2012.
5. X. Sun, W. Chen, and Y. Wang, "-Amyloid: the key peptide in the pathogenesis of Alzheimer's disease, " Frontiers in Pharmacology, vol. 6, pp. 1-9, 2015.
6. C. Cervellati, P. L. Wood, A. Romani et al., "Oxidative challenge in Alzheimer's disease: state of knowledge and future needs, " Journal of Investigative Medicine, vol. 64, no. 1, pp. 21-32, 2016.
7. B. De Strooper and E. Karran, "Thecellular phase ofAlzheimer's disease, " Cell, vol. 164, no. 4, pp. 603-615, 2016.
8. C. Spuch, S. Ortolano, and C. Navarro, "LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease, " Frontiers in Physiology, vol. 3, article 269, pp. 1-14, 2012.
9. S. H. Barage andK. D. Sonawane, "Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer's disease, " Neuropeptides, vol. 52, pp. 1-18, 2015.
10. G. simíc, M. B. Leko, S. Wray et al., "Tau protein hyperphosphorylation and aggregation in alzheimer's disease and other tauopathies, and possible neuroprotective strategies, " Biomolecules, vol. 6, no. 6, pp. 1-28, 2016.
11. A. Contestabile, "The history of the cholinergic hypothesis, " Behavioural Brain Research, vol. 221, no. 2, pp. 334-340, 2011.
12. J. Folch, I. Patraca, N. Martínez et al., "The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin, " Life Sciences, vol. 140, pp. 19-28, 2015.
13. L. Y. Di Marco, A. Venneri, E. Farkas, P. C. Evans, A. Marzo, and A. F. Frangi, "Vascular dysfunction in the pathogenesis of Alzheimer's disease-a review of endothelium-mediated mechanisms and ensuing vicious circles, " Neurobiology of Disease, vol. 82, pp. 593-606, 2015.
14. P. Gamba, G. Testa, S. Gargiulo, E. Staurenghi, G. Poli, and G. Leonarduzzi, "Oxidized cholesterol as the driving force behind the development of Alzheimer's disease, " Frontiers in Aging Neuroscience, vol. 7, article 119, 2015.
15. L. Xu, X. Wu, R. Li et al., "Prediction of progressive mild cognitive impairment by multi-modal neuroimaging biomarkers, " Journal of Alzheimer's Disease, vol. 51, no. 4, pp. 1045-1056, 2016.
16. S. Ramírez-Díaz, G. Albert-Meza, J. ávila-Fuentes et al., Enfermedad deAlzheimer: Presente y Futuro, Planeacíon yDesarrollo, Monterrey, Mexico, 2011.
17. A. Christensen and C. J. Pike, "Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease, " Frontiers in Aging Neuroscience, vol. 7, article 130, pp. 1-14, 2015.
18. Z. Chen andC. Zhong, "Oxidative stress inAlzheimer's disease, " Neuroscience Bulletin, vol. 30, no. 2, pp. 271-281, 2014.
19. L. B. Haim, M.-A. Carrillo-de Sauvage, K. Ceyzériat, and C. Escartin, "Elusive roles for reactive astrocytes in neurodegenerative diseases, " Frontiers in Cellular Neuroscience, vol. 9, article 278, pp. 1-27, 2015.
20. Y. Huang and R. W. Mahley, "Neurobiology of Disease Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases, " Neurobiology of Disease, vol. 72, pp. 3-12, 2014.
21. V. Van-Giau, E. Bagyinszky, S. S.-A. An, and S. Y. Kim, "Role of apolipoprotein E in neurodegenerative diseases, " Neuropsychiatric Disease and Treatment, vol. 11, pp. 1723-1737, 2015.
22. I. H. K. Dias, M. C. Polidori, and H. R. Griffiths, "Hypercholesterolaemia-induced oxidative stress at the blood-brain barrier, " Biochemical Society Transactions, vol. 42, no. 4, pp. 1001-1005, 2014.
23. Z. Xue-Shan, W. Qi, R. Zhong et al., "Imbalanced cholesterol metabolism in Alzheimer's disease, " Clinica Chimica Acta, vol. 456, pp. 107-114, 2016.
24. G. Verdile, K. N. Keane, V. F. Cruzat et al., "Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer's disease, " Mediators of Inflammation, vol. 2015, Article ID 105828, 17 pages, 2015.
25. J. M. Walker and F. E. Harrison, "Shared neuropathological characteristics of obesity, type 2 diabetes and Alzheimer's disease: impacts on cognitive decline, " Nutrients, vol. 7, no. 9, pp. 7332-7357, 2015.
26. R. F. de Bruijn and M. A. Ikram, "Cardiovascular risk factors and future risk of Alzheimer's disease, " BMC Medicine, vol. 12, no. 1, article 130, pp. 1-9, 2014.
27. D. A. Butterfield, F. Di Domenico, and E. Barone, "Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain, " Biochimica et Biophysica Acta-Molecular Basis ofDisease, vol. 1842, no. 9, pp. 1693-1706, 2014.
28. R. Sandhir and S. Gupta, "Molecular and biochemical trajectories from diabetes to Alzheimer's disease?: a critical appraisal, " World Journal of Diabetes, vol. 6, no. 12, pp. 1223-1242, 2015.
29. P. G. Ridge, M. T. Ebbert, and J. S. Kauwe, "Genetics of Alzheimer's disease, " BioMed Research International, vol. 2013, Article ID 254954, 13 pages, 2013.
30. D. M. Holtzman, J. Herz, and G. Bu, "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease, " Cold SpringHarbor Perspectives inMedicine, vol. 2, no. 3, Article ID a006312, 2012.
31. C.-C. Liu, T. Kanekiyo, H. Xu, and G. Bu, "Apolipoprotein e and Alzheimer disease: risk, mechanisms and therapy, " Nature Reviews Neurology, vol. 9, no. 2, pp. 106-118, 2013.
32. A. M. Manelli, W. B. Stine, L. J. Van Eldik, and M. J. LaDu, "ApoE andAbeta1-42 interactions: effects of isoformand conformation on structure and function, " Journal of Molecular Neuroscience, vol. 23, no. 3, pp. 235-246, 2004.
33. E. H. Corder, A. M. Saunders, W. J. Strittmatter et al., "Gene dose of apolipoprotein e type 4 allele and the risk of Alzheimer's disease in late onset families, " Science, vol. 261, no. 5123, pp. 921-923, 1993.
34. Y. Gu, Q. R. Razlighi, L. B. Zahodne et al., "Brain amyloid deposition and longitudinal cognitive decline in nondemented older subjects: results from a multi-ethnic population, " PLoS ONE, vol. 116, pp. 1-14, 2015.
35. J. B. S. Langbaum, K. Chen, R. J. Caselli et al., "Hypometabolism in Alzheimer-affected brain regions in cognitively healthy latino individuals carrying the apolipoprotein E 4 allele, " Archives of Neurology, vol. 67, no. 4, pp. 462-468, 2010.
36. L. Xie, H. Yan, L. Shi et al., "Association between CYP17A1 rs3824755 and rs743572 gene polymorphisms and Alzheimer's disease in the Chinese Han population, " Neuroscience Letters, vol. 618, pp. 77-82, 2016.
37. M.-X. Tang, G. Maestre, W.-Y. Tsai et al., "Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City, " The American Journal of Human Genetics, vol. 58, no. 3, pp. 574-584, 1996.
38. R. M. Corbo and R. Scacchp, "Apolipoprotein E (APOE) allele distribution in the world. Is APOE?4 a 'thrifty' allele" Annals of Human Genetics, vol. 63, no. 4, pp. 301-310, 1999.
39. Y. L. Chai, H. K.-H. Yeo, J. Wang et al., "Apolipoprotein 4 is associated with dementia and cognitive impairment predominantly due to Alzheimer's disease and not with vascular cognitive impairment: a Singapore-based cohort, " Journal of Alzheimer's Disease, vol. 51, no. 4, pp. 1111-1118, 2016.
40. R. Wang, L. Fratiglioni, E. J. Laukka et al., "Effects of vascular risk factors and APOE 4 on white matter integrity and cognitive decline, " Neurology, vol. 84, no. 11, pp. 1128-1135, 2015.
41. C. M. Karch and A. M. Goate, "Alzheimer's disease risk genes andmechanisms of disease pathogenesis, " Biological Psychiatry, vol. 77, no. 1, pp. 43-51, 2015.
42. J. R. P. Prasanthi, M. Schrag, B. Dasari et al., "Deferiprone reduces amyloid-and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet, " Journal of Alzheimer's Disease, vol. 30, no. 1, pp. 167-182, 2012.
43. S. Kosari, E. Badoer, J. C. D. Nguyen, A. S. Killcross, and T. A. Jenkins, "Effect of western and high fat diets on memory and cholinergic measures in the rat, " Behavioural Brain Research, vol. 235, no. 1, pp. 98-103, 2012.
44. W. L. F. Lim, I. J. Martins, and R. N. Martins, "The involvement of lipids in alzheimer's disease, " Journal of Genetics and Genomics, vol. 41, no. 5, pp. 261-274, 2014.
45. L. Puglielli, B. C. Ellis, A. J. Saunders, and D. M. Kovacs, "Ceramide stabilizes-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid-peptide biogenesis, " The Journal of Biological Chemistry, vol. 278, no. 22, pp. 19777-19783, 2003.
46. C. Marquer, V. Devauges, J.-C. Cossec et al., "Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis, " The FASEB Journal, vol. 25, no. 4, pp. 1295-1305, 2011.
47. L. K. Cuddy, W. Winick-Ng, and R. J. Rylett, "Regulation of the high-affinity choline transporter activity and trafficking by its association with cholesterol-rich lipid rafts, " Journal of Neurochemistry, vol. 128, no. 5, pp. 725-740, 2014.
48. V. A. M. Villar, S. Cuevas, X. Zheng, and P. A. Jose, "Localization and signaling of GPCRs in lipid rafts, " Methods in Cell Biology, vol. 132, pp. 3-23, 2016.
49. C. Ullrich, M. Pirchl, and C. Humpel, "Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits, "Molecular and Cellular Neuroscience, vol. 45, no. 4, pp. 408-417, 2010.
50. Y. Kim, C. Kim, H. Y. Jang, I. Mook-Jung, and B. Kim, "Inhibition of cholesterol biosynthesis reduces-secretase activity and amyloid-generation, " Journal of Alzheimer's Disease, vol. 51, no. 4, pp. 1057-1068, 2016.
51. E. Kojro, G. Gimpl, S. Lammich, W. März, and F. Fahrenholz, "Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the-secretase ADAM 10, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 10, pp. 5815-5820, 2001.
52. V. Vingtdeux and P. Marambaud, "Identification and biology of-secretase, " Journal of Neurochemistry, vol. 120, no. 1, pp. 34-45, 2012.
53. J. Popp, S. Meichsner, H. Kölsch et al., "Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease, " Biochemical Pharmacology, vol. 86, no. 1, pp. 37-42, 2013.
54. J. Poirier, J. Miron, C. Picard et al., "Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease, " Neurobiology of Aging, vol. 35, no. 2, pp. S3-S10, 2014.
55. G. Marwarha and O. Ghribi, "Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap" Experimental Gerontology, vol. 68, pp. 13-18, 2015.
56. V. Leoni and C. Caccia, "Oxysterols as biomarkers in neurodegenerative diseases, " Chemistry and Physics of Lipids, vol. 164, no. 6, pp. 515-524, 2011.
57. M. Sharma, M. Tiwari, and R. K. Tiwari, "Hyperhomocysteinemia: impact on neurodegenerative diseases, " Basic and Clinical Pharmacology and Toxicology, vol. 117, no. 5, pp. 287-296, 2015.
58. B. A. Maron and J. Loscalzo, "The treatment of hyperhomocysteinemia, " Annual Review of Medicine, vol. 60, pp. 39-54, 2009.
59. R. Poddar and S. Paul, "Homocysteine-NMDA receptormediated activation of extracellular signal-regulated kinase leads to neuronal cell death, " Journal of Neurochemistry, vol. 110, no. 3, pp. 1095-1106, 2009.
60. S. Li, M. Jin, T. Koeglsperger, N. E. Shepardson, G. M. Shankar, and D. J. Selkoe, "Soluble a oligomers inhibit long-termpotentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors, " Journal of Neuroscience, vol. 31, no. 18, pp. 6627-6638, 2011.
61. J. H. Birnbaum, J. Bali, L. Rajendran, R. M. Nitsch, and C. Tackenberg, "Calcium flux-independent NMDA receptor activity is required for A oligomer-induced synaptic loss, " Cell Death & Disease, vol. 6, no. 6, Article ID e1791, 2015.
62. M. Wiesmann, C. Capone, V. Zerbi et al., "Hypertension impairs cerebral blood flow in a mouse model for Alzheimer's disease, " Current Alzheimer Research, vol. 12, no. 10, pp. 914-922, 2015.
63. E. Joas, K. Bäckman, D. Gustafson et al., "Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years, " Hypertension, vol. 59, no. 4, pp. 796-801, 2012.
64. C. N. H. Abheiden, R. Van Doornik, A. M. Aukes, W. M. Van Der Flier, P. Scheltens, and C. J. M. De Groot, "Hypertensive disorders of pregnancy appear not to be associated with Alzheimer's disease later in life, " Dementia and Geriatric Cognitive Disorders Extra, vol. 5, no. 3, pp. 375-385, 2015.
65. Y. Lu, F. R. Day, S. Gustafsson et al., "New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk, " Nature Communications, vol. 7, Article ID 10495, 2016.
66. E. Pedditizi, R. Peters, and N. Beckett, "The risk of overweight/ obesity in mid-life and late life for the development of dementia: a systematic reviewandmeta-analysis of longitudinal studies, " Age and Ageing, vol. 45, no. 1, pp. 14-21, 2016.
67. J. P. Thaler, C.-X. Yi, E. A. Schur et al., "Obesity is associated with hypothalamic injury in rodents and humans, " The Journal of Clinical Investigation, vol. 122, no. 1, pp. 153-162, 2012.
68. D. J. Bonda, J. G. Stone, S. L. Torres et al., "Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance, " Journal of Neurochemistry, vol. 128, no. 1, pp. 162-172, 2014.
69. A. Jayaraman, D. Lent-Schochet, and C. J. Pike, "Diet-induced obesity and low testosterone increase neuroinflammation and impair neural function, " Journal of Neuroinflammation, vol. 11, article 162, 2014.
70. V. A. Moser and C. J. Pike, "Obesity and sex interact in the regulation of Alzheimer's disease, " Neuroscience & Biobehavioral Reviews, 2015.
71. N. D. Barnard, A. E. Bunner, and U. Agarwal, "Saturated and trans fats and dementia: a systematic review, " Neurobiology of Aging, vol. 35, supplement 2, pp. S65-S73, 2014.
72. M. C. Morris and C. C. Tangney, "Dietary fat composition and dementia risk, " Neurobiology of Aging, vol. 35, supplement 2, pp. S59-S64, 2014.
73. M. Maesako, M. Uemura, Y. Tashiro et al., "High fat diet enhances-site cleavage of amyloid precursor protein (APP) via promoting-site APP cleaving enzyme 1/adaptor protein 2/clathrin complex formation, " PLoS ONE, vol. 10, no. 9, Article ID e0131199, pp. 1-16, 2015.
74. E. M. Knight, I. V. A. Martins, S. Gümüsgöz, S. M. Allan, and C. B. Lawrence, "Neurobiology of Aging High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology, " Neurobiology of Aging, vol. 35, no. 8, pp. 1821-1832, 2014.
75. D. Petrov, I. Pedrós, G. Artiach et al., "High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents, " Biochimica et Biophysica Acta- Molecular Basis of Disease, vol. 1852, no. 9, pp. 1687-1699, 2015.
76. A. L. Fitzpatrick, L. H. Kuller, O. L. Lopez et al., "Midlife and late-life obesity and the risk of dementia: cardiovascular health study, " Archives of Neurology, vol. 66, no. 3, pp. 336-342, 2009.
77. C. A. Magalhães, M. G. Carvalho, L. P. Sousa, P. Caramelli, and K. B. Gomes, "Leptin in Alzheimer's disease, " Clinica Chimica Acta, vol. 450, pp. 162-168, 2015.
78. N. Qizilbash, J. Gregson, M. E. Johnson et al., "BMI and risk of dementia in two million people over two decades: a retrospective cohort study, " The Lancet Diabetes and Endocrinology, vol. 3, no. 6, pp. 431-436, 2015.
79. L. Letra, I. Santana, and R. Seiça, "Obesity as a risk factor for Alzheimer's disease: the role of adipocytokines, " Metabolic Brain Disease, vol. 29, no. 3, pp. 563-568, 2014.
80. T. L. Platt, T. L. Beckett, K. Kohler, D. M. Niedowicz, and M. P. Murphy, "Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease, " Neuroscience, vol. 315, pp. 162-174, 2016.
81. I. A. C. Arnoldussen, A. J. Kiliaan, and D. R. Gustafson, "Obesity and dementia: adipokines interact with the brain, " European Neuropsychopharmacology, vol. 24, no. 12, pp. 1982-1999, 2014.
82. A. Aguilar-Valles, W. Inoue, C. Rummel, and G. N. Luheshi, "Obesity, adipokines and neuroinflammation, " Neuropharmacology, vol. 96, pp. 124-134, 2015.
83. M. Ishii and C. Iadecola, "Adipocyte-derived factors in agerelated dementia and their contribution to vascular and Alzheimer pathology, " Biochimica et Biophysica Acta (BBA): Molecular Basis of Disease, vol. 1862, no. 5, pp. 966-974, 2016.
84. H. Münzberg, "Leptin-signaling pathways and leptin resistance, " Forum of Nutrition, vol. 63, pp. 123-132, 2010.
85. J. Ma, W. Zhang, H. Wang et al., "Peripheral blood adipokines and insulin levels in patients with Alzheimer's disease: a replication study and meta-analysis, " Current Alzheimer Research, vol. 13, no. 3, pp. 223-233, 2016.
86. P. Rajagopalan, A. W. Toga, C. R. Jack, M. W. Weiner, and P. M. Thompson, "Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly, " NeuroReport, vol. 24, no. 2, pp. 58-62, 2013.
87. A. Zeki Al Hazzouri, K. L. Stone, M. N. Haan, and K. Yaffe, "Leptin, mild cognitive impairment, and dementia among elderly women, " Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, vol. 68, no. 2, pp. 175-180, 2013.
88. H. Münzberg and M. G. Myers Jr., "Molecular and anatomical determinants of central leptin resistance, " Nature Neuroscience, vol. 8, no. 5, pp. 566-570, 2005.
89. S. J. Greco, A. Hamzelou, J. M. Johnston, M. A. Smith, J. W. Ashford, and N. Tezapsidis, "Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and-amyloid in neurons, " Biochemical and Biophysical Research Communications, vol. 414, no. 1, pp. 170-174, 2011.
90. G. H. Doherty, "Obesity and the ageing brain: could leptin play a role in neurodegeneration" Current Gerontology and Geriatrics Research, vol. 2011, Article ID 708154, 8 pages, 2011.
91. G. Marwarha, S. Raza, C. Meiers, and O. Ghribi, "Leptin attenuates BACE1 expression and amyloid-genesis via the activation of SIRT1 signaling pathway, " Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1842, no. 9, pp. 1587-1595, 2014.
92. G. V. Ronnett, S. Ramamurthy, A. M. Kleman, L. E. Landree, and S. Aja, "AMPK in the brain: its roles in energy balance and neuroprotection, " Journal of Neurochemistry, vol. 109, no. 1, pp. 17-23, 2009.
93. M. Dhar, G. A. Wayman, M. Zhu, T. J. Lambert, M. A. Davare, and S. M. Appleyard, "Leptin-induced spine formation requires TrpC channels and the CaM kinase cascade in the hippocampus, " The Journal of Neuroscience, vol. 34, no. 30, pp. 10022-10033, 2014.
94. Y. Takemura, K. Walsh, and N. Ouchi, "Adiponectin and cardiovascular inflammatory responses, " Current Atherosclerosis Reports, vol. 9, no. 3, pp. 238-243, 2007.
95. M. Blüher and C. S. Mantzoros, "From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century, " Metabolism: Clinical and Experimental, vol. 64, no. 1, pp. 131-145, 2015.
96. C. K. Chakraborti, "Role of adiponectin and some other factors linking type 2 diabetes mellitus and obesity, " World Journal of Diabetes, vol. 6, no. 15, pp. 1296-1308, 2015.
97. K.-H. Chan, K. S.-L. Lam, O.-Y. Cheng et al., "Adiponectin is protective against oxidative stress induced cytotoxicity in amyloid-beta neurotoxicity, " PLoS ONE, vol. 7, no. 12, Article ID e52354, 2012.
98. N. García-Casares, J. A. García-Arnés, J. Rioja et al., "Alzheimer's like brain changes correlate with low adiponectin plasma levels in type 2 diabetic patients, " Journal of Diabetes and Its Complications, vol. 30, no. 2, pp. 281-286, 2016.
99. L. Dukic, A.-M. Simundic, I. Martinic-Popovic et al., "The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia, " Clinical Biochemistry, vol. 49, no. 3, pp. 213-218, 2016.
100. G. Marwarha, S. Raza, J. R. P. Prasanthi, and O. Ghribi, "Gadd153 and NF-B crosstalk regulates 27-hydroxycholesterol-induced increase in BACE1 and-amyloid production in human neuroblastoma SH-SY5Y cells, " PLoS ONE, vol. 8, no. 8, Article ID e70773, 2013.
101. L. Bernardino, F. Agasse, B. Silva, R. Ferreira, S. Grade, and J. O. Malva, "Tumor necrosis factor-modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures, " StemCells, vol. 26, no. 9, pp. 2361-2371, 2008.
102. S. Li, J. Deng, H. Hou et al., "Specific antibody binding to the APP672-699 region shifts APP processing from-To-cleavage, " Cell Death and Disease, vol. 5, no. 8, Article ID e1374, 2014.
103. A. Eskilsson, E. Mirrasekhian, S. Dufour, M. Schwaninger, D. Engblom, and A. Blomqvist, "Immune-induced fever is mediated by IL-6 receptors on brain endothelial cells coupled to STAT3-dependent induction of brain endothelial prostaglandin synthesis, "TheJournal ofNeuroscience, vol. 34, no. 48, pp. 15957-15961, 2014.
104. L. Malmsten, S. Vijayaraghavan, O. Hovatta, A. Marutle, and T. Darreh-Shori, "Fibrillar-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation, " Journal of Cellular and Molecular Medicine, vol. 18, no. 9, pp. 1874-1888, 2014.
105. L. M. Qin, R. Bouchard, and S. Pugazhenthi, "Regulation of cyclic AMP response element-binding protein during neuroglial interactions, " Journal of Neurochemistry, vol. 136, no. 5, pp. 918-930, 2016.
106. M. Rios, "BDNF and the central control of feeding: accidental bystander or essential player" Trends in Neurosciences, vol. 36, no. 2, pp. 83-90, 2013.
107. J. C. Han, M. J. Muehlbauer, H. N. Cui, C. B. Newgard, and A. M. Haqq, "Lower brain-derived neurotrophic factor in patients with Prader-Willi syndrome compared to obese and lean control subjects, " The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 7, pp. 3532-3536, 2010.
108. F. Vanevski and B. Xu, "Molecular and neural bases underlying roles of BDNF in the control of body weight, " Frontiers in Neuroscience, vol. 7, article 37, pp. 1-9, 2013.
109. K. Marosi and M. P. Mattson, "BDNF mediates adaptive brain and body responses to energetic challenges, " Trends in Endocrinology and Metabolism, vol. 25, no. 2, pp. 89-98, 2014.
110. A. Benigni, P. Cassis, and G. Remuzzi, "Angiotensin II revisited: new roles in inflammation, immunology and aging, " EMBO Molecular Medicine, vol. 2, no. 7, pp. 247-257, 2010.
111. K. Mittal and D. P. Katare, "Shared links between type 2 diabetes mellitus and Alzheimer's disease: a review, " Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2016.
112. S. Rosales-Corral, D.-X. Tan, L. Manchester, and R. J. Reiter, "Diabetes and alzheimer disease, two overlapping pathologies with the same background: oxidative stress, " OxidativeMedicine and Cellular Longevity, vol. 2015, Article ID 985845, 14 pages, 2015.
113. K. Talbot, H.-Y. Wang, H. Kazi et al., "Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline, "The Journal of Clinical Investigation, vol. 122, no. 4, pp. 1316-1338, 2012.
114. T. Miyakawa, "Vascular pathology in Alzheimer's disease, " Psychogeriatrics, vol. 10, no. 1, pp. 39-44, 2010.
115. D. Kapogiannis and M. P. Mattson, "Perturbed energy metabolism and neuronal circuit dysfunction in cognitive impairment, " The Lancet Neurology, vol. 10, no. 2, pp. 187-198, 2011.
116. R. O. Domínguez, M. A. Pagano, E. R. Marschoff, S. E. González, M. G. Repetto, and J. A. Serra, "Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: associations and a hypothesis, " Neurologia, vol. 29, no. 9, pp. 567-572, 2014.
117. E. Calvo-Ochoa and C. Arias, "Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models, " Diabetes/Metabolism Research and Reviews, vol. 31, no. 1, pp. 1-13, 2015.
118. A. Kleinridders, W. Cai, L. Cappellucci et al., "Insulin resistance in brain alters dopamine turnover and causes behavioral disorders, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 11, pp. 3463-3468, 2015.
119. D. Nuzzo, P. Picone, S. Baldassano et al., "Insulin resistance as commonmolecular denominator linking obesity to Alzheimer's disease, " Current Alzheimer Research, vol. 12, no. 8, pp. 723-735, 2015.
120. E. S. Chan, C. Chen, G. M. Cole, and B.-S. Wong, "Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic mice, " Scientific Reports, vol. 5, Article ID 13842, 2015.
121. D. K. Shoemark and S. J. Allen, "The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer's disease, " Journal of Alzheimer's Disease, vol. 43, no. 3, pp. 725-738, 2015.
122. J. Qin, Y. Li, Z. Cai et al., "Ametagenome-wide association study of gut microbiota in type-2 diabetes, " Nature, vol. 490, pp. 55-60, 2012.
123. F. Scheperjan, "Can microbiota research change our understanding of neurodegenerative diseases" Neurodegenerative Disease Management, vol. 6, no. 2, pp. 81-85, 2016.
124. P. Maheshwari and G. D. Eslick, "Bacterial infection and Alzheimer's disease: a meta-analysis, " Journal of Alzheimer's Disease, vol. 43, no. 3, pp. 957-966, 2015.
125. R. Mancuso, F. Baglio, M. Cabinio et al., "Titers of herpes simplex virus type 1 antibodies positively correlate with grey matter volumes in Alzheimer's disease, " Journal of Alzheimer's Disease, vol. 38, no. 4, pp. 741-745, 2014.
126. R. P. Friedland, "Mechanisms of molecular mimicry involving the microbiota in neurodegeneration, " Journal of Alzheimer's Disease, vol. 45, no. 2, pp. 349-362, 2015.
127. C. M. Lema Tomé, T. Tyson, N. L. Rey, S. Grathwohl, M. Britschgi, and P. Brundin, "Inflammation and-synuclein's prion-like behavior in Parkinson's disease-is there a link" Molecular neurobiology, vol. 47, no. 2, pp. 561-574, 2013.
128. G. PérezMartínez, C. Bäuerl, and M. C. Collado, "Understanding gut microbiota in elderly's health will enable intervention through probiotics, " Beneficial Microbes, vol. 5, no. 3, pp. 235-246, 2014.
129. M. C. Collado, C. Bäueri, and G. Pérez-Martínez, "Defining microbiota for developing new probiotics, " Microbial Ecology in Health and Disease, vol. 23, pp. 35-39, 2012.
130. A. R. Kamer, R. G. Craig, E. Pirraglia et al., "TNF-and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects, " Journal of Neuroimmunology, vol. 216, no. 1-2, pp. 92-97, 2009.
131. A. Kumar, C. M. Nisha, C. Silakari et al., "Current and novel therapeutic molecules and targets in Alzheimer's disease, " Journal of the Formosan Medical Association, vol. 115, no. 1, pp. 3-10, 2016.
132. P. Scheltens, K. Blennow, M. M. Breteler et al., "Alzheimer's disease, " The Lancet, 2016.
133. L. Nelson andN. Tabet, "Slowing the progression of Alzheimer's disease; what works" Ageing Research Reviews, vol. 23, pp. 193-209, 2015.
134. D. Mitsushima, A. Sano, and T. Takahashi, "Acholinergic trigger drives learning-induced plasticity at hippocampal synapses, " Nature Communications, vol. 4, article 2760, 2013.
135. D. Puzzo, W. Gulisano, O. Arancio, and A. Palmeri, "The keystone of Alzheimer pathogenesis might be sought in A physiology, " Neuroscience, vol. 307, pp. 26-36, 2015.
136. A. Garcia-Osta and C. M. Alberini, "Amyloid beta mediates memory formation, " Learning and Memory, vol. 16, no. 4, pp. 267-272, 2009.
137. P. Anand and B. Singh, "A review on cholinesterase inhibitors forAlzheimer's disease, "Archives of Pharmacal Research, vol. 36, no. 4, pp. 375-399, 2013.
138. S. Andrieu, N. Coley, S. Lovestone, P. S. Aisen, and B. Vellas, "Prevention of sporadic Alzheimer's disease: lessons learned fromclinical trials and future directions, " The Lancet Neurology, vol. 14, no. 9, pp. 926-944, 2015.
139. J. Godýn, J. Jónczyk, D. Panek, and B. Malawska, "Therapeutic strategies for Alzheimer's disease in clinical trials, " Pharmacological Reports, vol. 68, no. 1, pp. 127-138, 2016.
140. J. Folch, D. Petrov, M. Ettcheto et al., "Current research therapeutic strategies for Alzheimer's disease treatment, " Neural Plasticity, vol. 2016, Article ID 8501693, 15 pages, 2016.
141. H. Prentice, J. P. Modi, and J.-Y. Wu, "Mechanisms of neuronal protection against excitotoxicity, endoplasmic reticulum stress, and mitochondrial dysfunction in stroke and neurodegenerative diseases, " Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 964518, 7 pages, 2015.
142. X. Shi, X. Lin, R. Hu, N. Sun, J. Hao, and C. Gao, "Toxicological differences between NMDA receptor antagonists and cholinesterase inhibitors, " American Journal of Alzheimer's Disease and Other Dementias, vol. 31, no. 5, pp. 405-412, 2016.
143. X. Wang, J. Blanchard, I. Grundke-Iqbal, and K. Iqbal, "Memantine attenuatesAlzheimer's disease-like pathology and cognitive impairment, " PLoSONE, vol. 10, no. 12, Article ID0145441, 2015.
144. M. Chen, "The maze of APP processing in Alzheimer's disease: where did we go wrong in reasoning" Frontiers in Cellular Neuroscience, vol. 9, article 186, pp. 1-10, 2015.
145. G. T. Corbett, F. J. Gonzalez, and K. Pahan, "Activation of peroxisome proliferator-activated receptor stimulates ADAM10-mediated proteolysis of APP, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 27, pp. 8445-8450, 2015.
146. M. Shukla, H. H. Htoo, P. Wintachai et al., "Melatonin stimulates the nonamyloidogenic processing of aPP through the positive transcriptional regulation of ADAM10 and ADAM17, " Journal of Pineal Research, vol. 58, no. 2, pp. 151-165, 2015.
147. A. A. Pimenova, A. Thathiah, B. De Strooper, and I. Tesseur, "Regulation of amyloid precursor protein processing by serotonin signaling, " PLoSONE, vol. 9, no. 1, Article IDe87014, 2014.
148. A. Fragkouli, E. C. Tsilibary, and A. K. Tzinia, "Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFADmice, " Neurobiology of Disease, vol. 70, pp. 179-189, 2014.
149. K. W. Menting and J. A. H. R. Claassen, "-Secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease, " Frontiers in Aging Neuroscience, vol. 6, article 165, 2014.
150. O. G. Tatarnikova, M. A. Orlov, and N. V. Bobkova, "Betaamyloid and Tau-protein: structure, interaction, and prion-like properties, " Biochemistry, vol. 80, no. 13, pp. 1800-1819, 2015.
151. A. M. Weissmiller, O. Natera-Naranjo, S. M. Reyna et al., "A-secretase inhibitor, but not a-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP, " PLoS ONE, vol. 10, no. 2, Article ID e0118379, 2015.
152. K. Takeo, N. Watanabe, T. Tomita, and T. Iwatsubo, "Contribution of the-secretase subunits to the formation of catalytic pore of presenilin 1 protein, "TheJournal of Biological Chemistry, vol. 287, no. 31, pp. 25834-25843, 2012.
153. K. Takeo, S. Tanimura, T. Shinoda et al., "Allosteric regulation of-secretase activity by a phenylimidazole-type-secretase modulator, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 29, pp. 10544-10549, 2014.
154. J. I. Jung, A. R. Price, T. B. Ladd et al., "Cholestenoic acid, an endogenous cholesterol metabolite, is a potent-secretase modulator, " Molecular Neurodegeneration, vol. 10, article 29, 2015.
155. M. Awasthi, S. Singh, V. P. Pandey, and U. N. Dwivedi, "Alzheimer's disease: an overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products, " Journal of the Neurological Sciences, vol. 361, pp. 256-271, 2016.
156. J. Kalra and A. Khan, "Reducing A load and tau phosphorylation: emerging perspective for treating Alzheimer's disease, " European Journal of Pharmacology, vol. 764, pp. 571-581, 2015.
157. A. Francioso, P. Punzi, A. Boffi et al., "-Sheet interfering molecules acting against-amyloid aggregation and fibrillogenesis, " Bioorganic and Medicinal Chemistry, vol. 23, no. 8, pp. 1671-1683, 2015.
158. M. Han, Y. Liu, Q. Tan et al., "Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease, " European Journal of Pharmacology, vol. 657, no. 1-3, pp. 104-110, 2011.
159. C. Stack, S. Jainuddin, C. Elipenahli et al., "Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity, " Human Molecular Genetics, vol. 23, no. 14, Article ID ddu080, pp. 3716-3732, 2014.
160. V. Melis, M. Magbagbeolu, J. E. Rickard et al., "Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models, " Behavioural Pharmacology, vol. 26, no. 4, pp. 353-368, 2015.
161. B. Bulic, M. Pickhardt, E.-M. Mandelkow, and E. Mandelkow, "Tau protein and tau aggregation inhibitors, " Neuropharmacology, vol. 59, no. 4-5, pp. 276-289, 2010.
162. H. K. I. Dias, C. L. R. Brown, M. C. Polidori, G. Y. H. Lip, and H. R. Griffiths, "LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention, " Clinical Science, vol. 129, no. 12, pp. 1195-1206, 2016.
163. F. C. Lin, Y. S. Chuang, H. M. Hsieh et al., "Early statin use and the progression of Alzheimer disease: a total population-based case-control study, " Medicine, vol. 94, no. 47, Article ID e2143, 2015.
164. S. M. Grundy, "Metabolic syndrome update, " Trends in Cardiovascular Medicine, vol. 26, no. 4, pp. 364-373, 2016.
165. K. Srikanthan, A. Feyh, H. Visweshwar, J. I. Shapiro, and K. Sodhi, "Systematic review ofmetabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in theWestVirginian population, " International Journal ofMedical Sciences, vol. 13, no. 1, pp. 25-38, 2016.
166. B. McGuinness, D. Craig, R. Bullock, and P. Passmore, "Statins for the prevention of dementia, " The Cochrane Database of Systematic Reviews, no. 2, Article ID CD003160, 2009.
167. K. Fukui, H. A. Ferris, and C. R. Kahn, "Effect of cholesterol reduction on receptor signaling in neurons, " The Journal of Biological Chemistry, vol. 290, no. 44, pp. 26383-26392, 2015.
168. V. Rani, G. Deep, R. K. Singh, K. Palle, and U. C. S. Yadav, "Oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies, " Life Sciences, vol. 148, no. 11, pp. 183-193, 2016.
169. L. M. Waite, "Treatment for Alzheimer's disease: has anything changed" Australian Prescriber, vol. 38, no. 2, pp. 60-63, 2015.
170. M. K. Jedrziewski, D. C. Ewbank, H. Wang, and J. Q. Trojanowski, "The impact of exercise, cognitive activities, and socialization on cognitive function: results from the national long-termcare survey, " American Journal of Alzheimer's Disease &OtherDementias, vol. 29, no. 4, pp. 372-378, 2014.
171. O. C. Okonkwo, S. A. Schultz, J. M. Oh et al., "Physical activity attenuates age-related biomarker alterations in preclinical AD, " Neurology, vol. 83, no. 19, pp. 1753-1760, 2014.
172. J. Verghese, R. B. Lipton, M. J. Katz et al., "Leisure activities and the risk of dementia in the elderly, "The New England Journal of Medicine, vol. 348, no. 25, pp. 2508-2516, 2003.
173. Y.-H. Sung, "Effects of treadmill exercise on hippocampal neurogenesis in an MPTP /probenecid-induced Parkinson's disease mouse model, " Journal of Physical Therapy Science, vol. 27, no. 10, pp. 3203-3206, 2015.
174. M. S. Nokia, S. Lensu, J. P. Ahtiainen et al., "Physical exercise increases adult hippocampal neurogenesis inmale rats provided it is aerobic and sustained, " The Journal of Physiology, vol. 594, no. 7, pp. 1855-1873, 2016.
175. R. B. Speisman, A. Kumar, A. Rani, T. C. Foster, and B. K. Ormerod, "Daily exercise improves memory, stimulates hippocampal neurogenesis and modulates immune and neuroimmune cytokines in aging rats, " Brain, Behavior, and Immunity, vol. 28, pp. 25-43, 2013.
176. T. Paillard, Y. Rolland, and P. S. de Barreto, "Protective effects of physical exercise in Alzheimer's disease and Parkinson's disease: a narrative review, " Journal of Clinical Neurology, vol. 11, no. 3, pp. 212-219, 2015.
177. P. Bekinschtein, C. A. Oomen, L. M. Saksida, and T. J. Bussey, "Effects of environmental enrichment and voluntary exercise on neurogenesis, learning and memory, and pattern separation: BDNF as a critical variable" Seminars in Cell & Developmental Biology, vol. 22, no. 5, pp. 536-542, 2011.
178. M. P. Mattson, "Lifelong brain health is a lifelong challenge. From evolutionary principles to empirical evidence, " Ageing Research Reviews, vol. 20, pp. 37-45, 2015.
179. M. J. Schafer, M. J. Alldred, S. H. Lee et al., "Reduction of-amyloid and-secretase by calorie restriction in female Tg2576 mice, " Neurobiology of Aging, vol. 36, no. 3, pp. 1293-1302, 2015.
180. L. Fratiglioni, S. Paillard-Borg, and B. Winblad, "An active and socially integrated lifestyle in late life might protect against dementia, " The Lancet Neurology, vol. 3, no. 6, pp. 343-353, 2004.
181. J. A. García-Casal, A. Loizeau, E. Csipke, M. Franco-Martín, M. V. Perea-Bartolomé, and M. Orrell, "Computer-based cognitive interventions for people living with dementia: a systematic literature review and meta-analysis, " Aging & Mental Health, 2016.
182. T. Kishi andK. Sunagawa, "Exercise training plus calorie restriction causes synergistic protection against cognitive decline via up-regulation of BDNF in hippocampus of stroke-prone hypertensive rats, " in Proceedings of the 34th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBS '12), pp. 6764-6767, San Diego, Calif, USA, August 2012.
183. Y. Kida and M. S. Goligorsky, "Sirtuins, cell senescence, and vascular aging, " Canadian Journal of Cardiology, vol. 32, no. 5, pp. 634-641, 2016.
184. I. Amigo and A. J. Kowaltowski, "Dietary restriction in cerebral bioenergetics and redox state, " Redox Biology, vol. 2, no. 1, pp. 296-304, 2014.
185. E. J. Dhurandhar, D. B. Allison, T. van Groen, and I. Kadish, "Hunger in the absence of caloric restriction improves cognition and attenuates alzheimer's disease pathology in a mouse model, " PLoS ONE, vol. 8, no. 4, Article ID e60437, 2013.
186. R. Mushtaq, S. Shoib, T. Shah, and S. Mushtaq, "Relationship between loneliness, psychiatric disorders and physical health A review on the psychological aspects of loneliness, " Journal of Clinical and Diagnostic Research, vol. 8, no. 9, pp. WE01-WE04, 2014.
187. C. A. de Jager, A. Oulhaj, R. Jacoby, H. Refsum, and A. D. Smith, "Cognitive and clinical outcomes of homocysteine-lowering Bvitamin treatment inmild cognitive impairment: a randomized controlled trial, " International Journal of Geriatric Psychiatry, vol. 27, no. 6, pp. 592-600, 2012.
188. H. Kim, G. Kim, W. Jang, S. Y. Kim, and N. Chang, "Association between intake of B vitamins and cognitive function in elderly Koreans with cognitive impairment, " Nutrition Journal, vol. 13, no. 1, article 118, pp. 1-11, 2014.
189. Y. Sun, C.-J. Lu, K.-L. Chien, S.-T. Chen, and R.-C. Chen, "Efficacy ofmultivitamin supplementation containing vitamins b6 and b12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese Patients, " Clinical Therapeutics, vol. 29, no. 10, pp. 2204-2214, 2007.
190. A. H. Ford, L. Flicker, H. Alfonso et al., "Vitamins B12, B6, and folic acid for cognition in older men, " Neurology, vol. 75, no. 17, pp. 1540-1547, 2010.
191. R. C. Petersen, R. G. Thomas, M. Grundman et al., "Vitamin E and donepezil for the treatment of mild cognitive impairment, " The New England Journal ofMedicine, vol. 352, no. 23, pp. 2379-2388, 2005.
192. S. Arlt, T. Müller-Thomsen, U. Beisiegel, and A. Kontush, "Effect of one-year vitamin C-and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease, " Neurochemical Research, vol. 37, no. 12, pp. 2706-2714, 2012.
193. A. K. Gangwar, A. Rawat, S. Tiwari, S. C. Tiwari, J. Narayan, and S. Tiwari, "Role of Vitamin-D in the prevention and treatment of Alzheimer's disease, " Indian Journal of Physiology and Pharmacology, vol. 59, no. 1, pp. 94-99, 2015.
194. J. L. Barranco-Quintana, M. F. Allam, A. S. Del Castillo, and R. F. Navajas, "Risk factors for Alzheimer's disease, " Revue Neurologique, vol. 40, no. 10, pp. 613-618, 2005.
195. A. Giacosa, A. F. Adam-Blondon, S. Baer-Sinnott et al., "Alcohol and wine in relation to cancer and other diseases, " European Journal of Cancer Prevention, vol. 21, no. 1, pp. 103-108, 2012.
196. D. Cutuli, P. De Bartolo, P. Caporali et al., "n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice, " Frontiers in Aging Neuroscience, vol. 6, article 220, pp. 1-17, 2014.
197. H. Nasri, A. Baradaran, H. Shirzad, and M. Rafeian-Kopaei, "New concepts in nutraceuticals as alternative for pharmaceuticals, " International Journal of Preventive Medicine, vol. 5, no. 12, pp. 1487-1499, 2014.
198. F. I. Baptista, A. G. Henriques, A. M. S. Silva, J. Wiltfang, and O. A. B. da Cruz E Silva, "Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease, " ACS Chemical Neuroscience, vol. 5, no. 2, pp. 83-92, 2014.
199. I. Solanki, P. Parihar, M. L. Mansuri, and M. S. Parihar, "Flavonoid-based therapies in the early management of neurodegenerative diseases, " Advances in Nutrition, vol. 6, no. 1, pp. 64-72, 2015.
200. M. P. Corcoran, D. L. McKay, and J. B. Blumberg, "Flavonoid basics: chemistry, sources, mechanisms of action, and safety, " Journal of Nutrition in Gerontology and Geriatrics, vol. 31, no. 3, pp. 176-189, 2012.
201. G. Desideri, C. Kwik-Uribe, D. Grassi et al., "Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study, " Hypertension, vol. 60, no. 3, pp. 794-801, 2012.
202. H. B. Boudouda, A. Zaghib, A. Karioti et al., "Antibacterial, antioxidant, anti-cholinesterase potential and flavonol glycosides of Biscutella raphanifolia (Brassicaceae), " Pakistan Journal of Pharmaceutical Sciences, vol. 28, no. 1, pp. 153-158, 2015.
203. T. Y. Lin, C. W. Lu, C. C. Chang, S. K. Huang, and S. J. Wang, "Luteolin inhibits the release of glutamate in rat cerebrocortical nerve terminals, " Journal of Agricultural and Food Chemistry, vol. 59, no. 15, pp. 8458-8466, 2011.
204. J. A. Baur and D. A. Sinclair, "Therapeutic potential of resveratrol: the in vivo evidence, " Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493-506, 2006.
205. T. Ma, M.-S. Tan, J.-T. Yu, and L. Tan, "Resveratrol as a therapeutic agent for Alzheimer's disease, " BioMed Research International, vol. 2014, Article ID 350516, 13 pages, 2014.
206. G. T. Diaz-Gerevini, G. Repossi, A. Dain, M. C. Tarres, U. N. Das, and A. R. Eynard, "Beneficial action of resveratrol: howand why" Nutrition, vol. 32, no. 2, pp. 174-178, 2016.
207. Y. A. Kim, G.-Y. Kim, K.-Y. Park, and Y. H. Choi, "Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia, " Journal of Medicinal Food, vol. 10, no. 2, pp. 218-224, 2007.
208. S. Bastianetto, C. Ménard, and R. Quirion, "Neuroprotective action of resveratrol, " Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease, vol. 1852, no. 6, pp. 1195-1201, 2015.
209. J. Chen, Y. Zhou, S. Mueller-Steiner et al., "SIRT1 protects against microglia-dependent amyloid-toxicity through inhibitingNF-Bsignaling, "The Journal of Biological Chemistry, vol. 280, no. 48, pp. 40364-40374, 2005.
210. J. A. Godoy, J. A. Rios, J. M. Zolezzi, N. Braidy, and N. C. Inestrosa, "Signaling pathway cross talk in Alzheimer's disease, " Cell Communication and Signaling, vol. 12, article 23, 2014.
211. D. Y. Yoo, J. H. Choi, W. Kim et al., "Effects of luteolin on spatial memory, cell proliferation, and neuroblast differentiation in the hippocampal dentate gyrus in a scopolamine-induced amnesia model, " Neurological Research, vol. 35, no. 8, pp. 813-820, 2013.
212. M. Zhu, D. Chen, D. Li et al., "Luteolin inhibits angiotensin IIinduced humanumbilical vein endothelial cell proliferation and migration through downregulation of src and Akt phosphorylation, " Circulation Journal, vol. 77, no. 3, pp. 772-779, 2013.
213. M. López-Lázaro, "Distribution and biological activities of the flavonoid luteolin, "Mini-Reviews inMedicinal Chemistry, vol. 9, no. 1, pp. 31-59, 2009.
214. F. Casamenti, C. Grossi, S. Rigacci, D. Pantano, I. Luccarini, and M. Stefani, "Oleuropein aglycone: a possible drug against degenerative conditions. In vivo evidence of its effectiveness against Alzheimer's disease, " Journal of Alzheimer's Disease, vol. 45, no. 3, pp. 679-688, 2015.
215. H. I. H. El-Sayyad, "Cholesterol overload impairing cerebellar function: the promise of natural products, " Nutrition, vol. 31, no. 5, pp. 621-630, 2015.
216. A. Safouris, G. Tsivgoulis, T. N. Sergentanis, and T. Psaltopoulou, "Mediterranean diet and risk of dementia, " Current Alzheimer Research, vol. 12, no. 8, pp. 736-744, 2015.
217. M. Baumgart, H. M. Snyder, M. C. Carrillo, S. Fazio, H. Kim, and H. Johns, "Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective, " Alzheimer's and Dementia, vol. 11, no. 6, pp. 718-726, 2015.
218. N. Hu, J.-T. Yu, L. Tan, Y.-L. Wang, L. Sun, and L. Tan, "Nutrition and the risk ofAlzheimer's disease, " BioMed Research International, vol. 2013, Article ID 524820, 12 pages, 2013.
219. S. H. Duncan and H. J. Flint, "Probiotics and prebiotics and health in ageing populations, " Maturitas, vol. 75, no. 1, pp. 44-50, 2013.
220. C.-S. Lin, C.-J. Chang, C.-C. Lu et al., "Impact of the gut microbiota, prebiotics, and probiotics on human health and disease, " Biomedical Journal, vol. 37, no. 5, pp. 259-268, 2014.
221. J. Liu, J. Sun, F. Wang et al., "Neuroprotective effects of Clostridium butyricum against vascular dementia in mice via metabolic butyrate, " BioMed Research International, vol. 2015, Article ID 412946, 12 pages, 2015.
222. D. Prescott, J. Lee, and D. J. Philpott, "An epithelial armamentarium to sense the microbiota, " Seminars in Immunology, vol. 25, no. 5, pp. 323-333, 2013.
223. G. Divyashri, G. Krishna, Muralidhara, and S. G. Prapulla, "Probiotic attributes, antioxidant, anti-inflammatory and neuromodulatory effects of Enterococcus faeciumCFR 3003: in vitro and in vivo evidence, " Journal of Medical Microbiology, vol. 64, no. 12, pp. 1527-1540, 2015.
224. W.-H. Liu, H.-L. Chuang, Y.-T. Huang et al., "Alteration of behavior and monoamine levels attributable to Lactobacillus plantarum PS128 in germ-free mice, " Behavioural Brain Research, vol. 298, pp. 202-209, 2016.